Multiple Sclerosis
Conditions
Interventions
None listed
Sponsors
Osaka University Department of Neurology, Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with MS aged 20 years or older who visited Osaka University Hospital will be eligible. MS patients who meet the following specific criteria will be included. <eligibility criteria> Meet the 2017 McDonald's diagnostic criteria. Has a history of treatment with DMD. Has received or will receive at least one mRNA vaccination against SARS-CoV-2 at the time of consent. Age at the time of consent: 20 years or older. Has given or will give written consent to participate in the study.
Exclusion criteria
Exclusion criteria: Has been infected with SARS-CoV-2 virus up to 3 months after the second mRNA vaccination against SARS-CoV-2. Known allergy or contraindication to any vaccine component. Has received treatment with another vaccine within 4 weeks of the first SARS-CoV-2 mRNA vaccine. Participating in another clinical trial. Has used steroids within 3 months of the first SARS-CoV-2 mRNA vaccine and within 3 months of the second dose. Received intravenous or subcutaneous immunoglobulin (IVIG/SCIG) within 3 months after the first or second dose of SARS-CoV-2 mRNA vaccine. Other cases in which the attending physician deems it inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody titer against SARS-CoV-2 spike protein (RBD) | — |
Secondary
| Measure | Time frame |
|---|---|
| FACS analysis of peripheral blood PBMCs Gene expression analysis of PBMCs by RNA-seq | — |
Countries
Japan
Contacts
Public ContactTatsusada Okuno
Osaka University Department of Neurology, Osaka University Graduate School of Medicine
Outcome results
None listed